Telix Pharmaceuticals (TLX) Retained Earnings (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Retained Earnings for 3 consecutive years, with $101.6 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 2.11% to $101.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $101.6 million through Dec 2025, down 2.11% year-over-year, with the annual reading at $101.6 million for FY2025, 166.42% up from the prior year.
  • Retained Earnings for Q4 2025 was $101.6 million at Telix Pharmaceuticals, down from $103.8 million in the prior quarter.
  • The five-year high for Retained Earnings was $103.8 million in Q4 2024, with the low at -$171.6 million in Q4 2023.
  • Average Retained Earnings over 3 years is $11.2 million, with a median of $101.6 million recorded in 2025.
  • The sharpest move saw Retained Earnings soared 160.45% in 2024, then decreased 2.11% in 2025.
  • Over 3 years, Retained Earnings stood at -$171.6 million in 2023, then soared by 160.45% to $103.8 million in 2024, then dropped by 2.11% to $101.6 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $101.6 million, $103.8 million, and -$171.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.